Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Narumi Nakagiri
DAIW
Narumi Nakagiri
Daiwa
Wall Street Analyst
★★★★☆
#585
on 13Foresight · ranked by our own returns
83%
Success Rate
+20.8%
Average Return
10 of 12 calls profitable · +3.4% vs benchmark
📈 Across the calls we could measure, roughly 83% of Narumi Nakagiri's ratings turned a profit when each position was held for 2 year — averaging +20.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

5 Buy 5 Hold 0 Sell
Narumi's Stock Coverage 12 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return
ILMN
Illumina
 May 14, 2026 BUY Buy
-9.2% avg upside
30 analysts
$155.00
2.59% Downside
 +11.1%
ABT
Abbott Laboratories
 Apr 21, 2026 HOLD Strong Buy
+30.9% avg upside
35 analysts
$92.00
3.89% Upside
 -4.5%
PFE
Pfizer
 Feb 12, 2026 HOLD Buy
+31.7% avg upside
45 analysts
$27.00
4.20% Upside
 -3.8%
LLY
Eli Lilly & Co
 Dec 16, 2025 BUY Strong Buy
-11.2% avg upside
47 analysts
$1230.00
10.69% Upside
 +7.8%
GILD
Gilead Sciences
 Aug 18, 2025 BUY Strong Buy
-5.6% avg upside
66 analysts
$128.00
1.95% Upside
 +7.6%
ABBV
AbbVie
 Aug 07, 2025 BUY Buy
+1.3% avg upside
43 analysts
$214.00
3.17% Downside
 +13.9%
BMY
Bristol-Myers Squibb
 Aug 05, 2025 HOLD Buy
+7.4% avg upside
42 analysts
$42.00
24.06% Downside
 +29.1%
EW
Edwards Lifesciences
 Jul 29, 2025 BUY Strong Buy
+12.1% avg upside
34 analysts
$89.00
2.77% Upside
 +7.2%
MRK
Merck & Company
 Nov 11, 2024 HOLD Strong Buy
+9.8% avg upside
43 analysts
 — +20.2%
JNJ
Johnson & Johnson
 Jul 23, 2024 HOLD Strong Buy
-5.2% avg upside
36 analysts
$150.00
35.93% Downside
 +63.4%
AMGN
Amgen
 Dec 21, 2023 BUY Buy
-12.2% avg upside
57 analysts
$320.00
6.25% Downside
 +24.7%
VRTX
Vertex Pharmaceuticals
 Jun 11, 2021 HOLD Strong Buy
-3.9% avg upside
61 analysts
$210.00
54.24% Downside
 +73.1%
🔒 7 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Narumi Nakagiri — Frequently Asked Questions
How accurate are Narumi Nakagiri's stock ratings?
Based on the calls 13Foresight could measure, about 67% of Narumi's ratings were profitable over a one-year hold, with an average return of +8.8% per rating, or -3.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Narumi ranked on 13Foresight?
Narumi Nakagiri is currently ranked #585 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Narumi cover?
Narumi most recently has ratings on ILMN, ABT, PFE, LLY, GILD, ABBV, BMY, EW, MRK, JNJ, AMGN, VRTX. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.